Technology | Left Atrial Appendage (LAA) Occluders | April 29, 2016

AtriCure Receives FDA Clearance for New AtriClip Device

AtriClip PRO2 LAA Exclusion System features a streamlined hoopless end effector

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance

April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.

The new system features an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers and a hoopless end effector. The ambidextrous locking and trigger-style clip closing mechanism allows the operator to maintain focus on the LAA while maneuvering the device. The handle-based active articulation levers allow the operator to steer the end effector without removing the device. The hoopless end effector enhances anatomical visualization, and simplifies removal of the applier after deployment of the clip.

“The AtriClip PRO2 system provides easier placement of the proven AtriClip LAA occlusion technology,” said J. Michael Smith, M.D. at TriHealth Heart Institute in Cincinnati. “The new deployment system facilitates less invasive treatment of the LAA, including right chest approaches in conjunction with valve replacement and cardiac ablation procedures.”

For more information: www.atricure.com


Related Content

News | Atrial Fibrillation

August 31, 2023 — Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or ...

Home August 31, 2023
Home
News | Atrial Fibrillation

August 24, 2023 — GE HealthCare announces the launch of CardioVisio for Atrial Fibrillation (AFib), a digital tool ...

Home August 24, 2023
Home
News | Atrial Fibrillation

August 23, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of ...

Home August 23, 2023
Home
News | Atrial Fibrillation

July 21, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home July 21, 2023
Home
News | Atrial Fibrillation

July 7, 2023 — Atrial fibrillation (AFib) is the most common type of heart arrhythmia. This serious condition occurs ...

Home July 07, 2023
Home
News | Atrial Fibrillation

June 30, 2023 — Women with atrial fibrillation progress more rapidly to cognitive impairment and dementia than men with ...

Home June 30, 2023
Home
News | Atrial Fibrillation

May 26, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of Americans ...

Home May 26, 2023
Home
News | Atrial Fibrillation

May 18, 2023 — Vektor Medical, pioneers of technology to accurately map arrhythmias using only 12-lead ECG data ...

Home May 18, 2023
Home
News | Atrial Fibrillation

May 17, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmiatreatment and part of Johnson & Johnson ...

Home May 17, 2023
Home
News | Atrial Fibrillation

May 8, 2023 — An innovative three-step ablation approach including ethanol infusion of the vein of Marshall improves ...

Home May 08, 2023
Home
Subscribe Now